Cover Image
市場調查報告書

Momenta Pharmaceuticals, Inc.的產品平台分析

Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 256134
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
Momenta Pharmaceuticals, Inc.的產品平台分析 Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日期: 2016年07月13日 內容資訊: 英文 45 Pages
簡介

本報告提供Momenta Pharmaceuticals, Inc.上的治療藥開發平台現狀及各開發階段比較分析,提供藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,以及最新的企業新聞和發表,後期階段及中止計劃的相關資訊等。

Momenta Pharmaceuticals, Inc.的基本資料

Momenta Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Momenta Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Momenta Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Momenta Pharmaceuticals, Inc.:開發中產品概況

  • 位於臨床實驗階段的開發中產品
    • 位於第一階段的產品/聯合治療模式
  • 位於初期階段的開發中產品
    • 位於前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Momenta Pharmaceuticals, Inc.:藥物簡介

  • M-402
  • 自體免疫疾病及發炎性疾病用抗體
  • M-834
  • M-923
  • M-511

Momenta Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各類型分子
  • 各作用機制

Momenta Pharmaceuticals, Inc.:最近的開發平台趨勢

Momenta Pharmaceuticals, Inc.:暫停中的計劃

Momenta Pharmaceuticals, Inc.:企業發表

Momenta Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08089CDB

Summary

Global Markets Direct's, 'Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Momenta Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Momenta Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Momenta Pharmaceuticals, Inc.
  • The report provides overview of Momenta Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Momenta Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Momenta Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Momenta Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Momenta Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Momenta Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Momenta Pharmaceuticals, Inc. Snapshot
    • Momenta Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Momenta Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Momenta Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Momenta Pharmaceuticals, Inc. - Pipeline Products Glance
    • Momenta Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Momenta Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Momenta Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Momenta Pharmaceuticals, Inc. - Drug Profiles
    • adalimumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • necuparanib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-281
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • abatacept biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody for Autoimmune Disorders and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-230
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-615
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-706
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-710
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-730
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-740
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Autoimmune Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Momenta Pharmaceuticals, Inc. - Pipeline Analysis
    • Momenta Pharmaceuticals, Inc. - Pipeline Products by Target
    • Momenta Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Momenta Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Momenta Pharmaceuticals, Inc. - Dormant Projects
  • Momenta Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • bevacizumab biosimilar
  • Momenta Pharmaceuticals, Inc. - Company Statement
  • Momenta Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Momenta Pharmaceuticals, Inc., Key Information
  • Momenta Pharmaceuticals, Inc., Key Facts
  • Momenta Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Momenta Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Momenta Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Momenta Pharmaceuticals, Inc. - Phase III, 2016
  • Momenta Pharmaceuticals, Inc. - Phase II, 2016
  • Momenta Pharmaceuticals, Inc. - Phase I, 2016
  • Momenta Pharmaceuticals, Inc. - Preclinical, 2016
  • Momenta Pharmaceuticals, Inc. - Discovery, 2016
  • Momenta Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Momenta Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Momenta Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Momenta Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Momenta Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016
  • Momenta Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Momenta Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Momenta Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Momenta Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Momenta Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016
  • Momenta Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Momenta Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Momenta Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top